See more : Dayou A-Tech Co.,Ltd (002880.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Unrivaled Brands, Inc. (UNRV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Unrivaled Brands, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Augwind Energy Tech Storage Ltd (AUGN.TA) Income Statement Analysis – Financial Results
- AI TRANSPORTATION ACQUISITION CORP Ordinary shares (AITR) Income Statement Analysis – Financial Results
- Shengjing Bank Co., Ltd. (2066.HK) Income Statement Analysis – Financial Results
- Minaurum Gold Inc. (MGG.V) Income Statement Analysis – Financial Results
- AVEO Pharmaceuticals, Inc. (AVEO) Income Statement Analysis – Financial Results
Unrivaled Brands, Inc. (UNRV)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.unrivaledbrands.com
About Unrivaled Brands, Inc.
Unrivaled Brands, Inc. cultivates, produces, distributes, and retails medical and adult use cannabis products in California, Oregon, and Nevada. It also operates medical marijuana retail and adult use dispensaries, cultivation, and production facilities. The company was formerly known as Terra Tech Corp. and changed its name to Unrivaled Brands, Inc. in July 2021. Unrivaled Brands, Inc. was founded in 2010 and is based in Santa Ana, California.
Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 52.02M | 47.67M | 14.29M | 28.05M | 31.33M | 35.80M | 25.33M | 9.98M | 7.09M | 2.13M | 552.58K | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 35.12M | 35.71M | 10.69M | 13.40M | 18.90M | 30.32M | 22.76M | 8.96M | 6.94M | 2.04M | 451.71K | 0.00 | 0.00 | 0.00 |
Gross Profit | 16.90M | 11.97M | 3.60M | 14.65M | 12.43M | 5.48M | 2.57M | 1.02M | 152.99K | 88.92K | 100.87K | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 32.48% | 25.10% | 25.20% | 52.24% | 39.68% | 15.30% | 10.16% | 10.19% | 2.16% | 4.18% | 18.25% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 52.04M | 46.99M | 24.41M | 43.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.99K | 16.44K | 17.33K |
Selling & Marketing | 2.12M | 1.27M | 190.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 54.16M | 48.26M | 24.60M | 45.32M | 43.30M | 25.36M | 20.72M | 9.83M | 18.33M | 3.58M | 1.07M | 28.99K | 16.44K | 17.33K |
Other Expenses | 156.50M | -433.00K | 964.00K | 144.00K | 0.00 | 565.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 210.66M | 48.26M | 24.60M | 45.32M | 43.30M | 25.36M | 20.72M | 9.83M | 18.33M | 3.58M | 1.07M | 28.99K | 16.44K | 17.33K |
Cost & Expenses | 245.78M | 83.96M | 35.29M | 58.72M | 62.20M | 55.68M | 43.48M | 18.79M | 25.27M | 5.61M | 1.52M | 28.99K | 16.44K | 17.33K |
Interest Income | 4.17M | 1.78M | 1.39M | 9.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 4.17M | 1.78M | 2.93M | 9.30M | 13.09M | 2.68M | 1.79M | 1.17M | 1.10M | 1.28M | 62.20K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 13.40M | 8.96M | 964.00K | 6.29M | 4.98M | 3.65M | 2.54M | 645.29K | 438.78K | 41.31K | 14.09K | 0.00 | 0.00 | 0.00 |
EBITDA | -193.76M | -29.15M | -12.76M | -39.29M | -24.48M | -16.23M | -18.15M | -8.17M | -17.74M | -3.45M | -957.91K | -28.99K | -16.44K | -17.33K |
EBITDA Ratio | -372.51% | -57.33% | -140.25% | -86.91% | -84.74% | -45.34% | -71.65% | -81.92% | -250.00% | -162.08% | -173.35% | 0.00% | 0.00% | 0.00% |
Operating Income | -193.76M | -36.29M | -21.00M | -30.67M | -30.87M | -19.88M | -18.15M | -8.82M | -18.17M | -3.49M | -5.77M | -28.99K | -16.44K | -17.33K |
Operating Income Ratio | -372.51% | -76.12% | -147.00% | -109.33% | -98.52% | -55.53% | -71.65% | -88.39% | -256.19% | -164.03% | -1,044.55% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -1.87M | -5.89M | -9.12M | -17.77M | -8.60M | -13.65M | -9.84M | -546.10K | -3.99M | -2.66M | -63.53K | 0.00 | 0.00 | 0.00 |
Income Before Tax | -195.63M | -42.18M | -13.80M | -48.44M | -39.47M | -33.53M | -27.99M | -9.36M | -22.17M | -6.15M | -5.84M | -28.99K | -16.44K | -17.33K |
Income Before Tax Ratio | -376.11% | -88.47% | -96.59% | -172.70% | -125.98% | -93.66% | -110.49% | -93.86% | -312.46% | -289.14% | -1,056.05% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | -2.78M | 885.00K | 13.04M | 6.87M | 279.61K | -347.46K | -1.07M | 44.00K | 13.46K | 1.65K | 879.00 | 28.99K | 16.44K | 17.33K |
Net Income | -192.85M | -43.06M | -26.84M | -55.31M | -39.75M | -32.68M | -26.92M | -9.23M | -21.89M | -6.15M | -5.84M | -28.99K | -16.44K | -17.33K |
Net Income Ratio | -370.76% | -90.33% | -187.88% | -197.17% | -126.87% | -91.28% | -106.28% | -92.48% | -308.55% | -289.22% | -1,056.21% | 0.00% | 0.00% | 0.00% |
EPS | -0.33 | -0.11 | -0.14 | -0.52 | -0.56 | -0.71 | -0.93 | -0.52 | -1.88 | -0.93 | -1.14 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -0.33 | -0.11 | -0.14 | -0.52 | -0.56 | -0.71 | -0.93 | -0.52 | -1.88 | -0.93 | -1.14 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 589.55M | 376.63M | 191.98M | 106.04M | 71.03M | 46.07M | 28.84M | 17.79M | 11.62M | 6.60M | 5.13M | 79.69M | 100.18M | 100.00M |
Weighted Avg Shares Out (Dil) | 589.55M | 376.63M | 191.98M | 106.04M | 71.03M | 46.07M | 28.84M | 17.79M | 11.62M | 6.60M | 5.13M | 79.69M | 100.18M | 100.00M |
Unrivaled Brands celebrates grand reopening of Blüm San Leandro cannabis retail dispensary
Unrivaled Brands inks agreement to raise up to $2M in a private placement of newly designated Series V Class of preferred stock
Unrivaled Brands to focus on California operations as it bolsters management team
Unrivaled Brands successfully opposes another application for emergency relief by People's California
Unrivaled Brands posts revenue of $10.76M for Q3 2022
Unrivaled Brands sues People's California managing directors for alleged fraud related to cannabis dispensary deal
Unrivaled Brands adds veteran cannabis financial expert Patty Chan as interim CFO
Unrivaled Brands taps experienced corporate attorney Robert Baca as Interim Chief Legal Officer
Unrivaled Brands reports sixfold increase in 2Q revenue; gross profit more than triples
Unrivaled Brands to expand board of directors; launches national search
Source: https://incomestatements.info
Category: Stock Reports